Needham & Company LLC reissued their buy rating on shares of Immunocore (NASDAQ:IMCR - Free Report) in a report issued on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $71.00 price target on the stock.
Other analysts also recently issued research reports about the stock. Morgan Stanley reaffirmed an "equal weight" rating and issued a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $65.64.
Read Our Latest Analysis on Immunocore
Immunocore Price Performance
IMCR traded up $0.53 during trading on Wednesday, reaching $28.80. 345,561 shares of the stock were exchanged, compared to its average volume of 432,123. Immunocore has a 1 year low of $27.19 and a 1 year high of $66.00. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -30.32 and a beta of 0.79. The business's 50 day moving average price is $30.08 and its two-hundred day moving average price is $31.31. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in Immunocore by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock worth $1,047,000 after buying an additional 420 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Immunocore in the fourth quarter valued at about $25,000. China Universal Asset Management Co. Ltd. grew its position in shares of Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after buying an additional 960 shares in the last quarter. NEOS Investment Management LLC raised its holdings in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after acquiring an additional 1,102 shares in the last quarter. Finally, Pier Capital LLC grew its holdings in Immunocore by 1.4% during the 3rd quarter. Pier Capital LLC now owns 82,480 shares of the company's stock worth $2,568,000 after acquiring an additional 1,174 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.
Immunocore Company Profile
(
Get Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Featured Stories
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
